GSK at a glance

We are a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together.

We prioritise innovation in vaccines and specialty medicines to prevent and treat disease.

A focused biopharma company

  • People worldwide

    70k
  • Countries we operate in

    >75
  • Manufacturing sites

    37

Innovation

  • R&D investment in 2023 (£)

    6.2bn
  • Global R&D centres in US, UK, Belgium and Italy

    4
  • Major business development deals in 2023

    6

Performance

  • Packs of medicines and doses of vaccines delivered

    2.3bn
  • Vaccine and medicine sales in 2023 (£)

    30.3bn
  • Sales growth in 2023

    14%
  • Sales of products launched in the last five years including lifecycle innovation (£)

    10.0bn

Trust

  • In the Access to Medicine Index

    1st
  • In our industry for the S&P Global Corporate Sustainability Assessment

    1st
  • Reduction in Operational Carbon emissions

    10%
  • Global Health pipeline assets progressed to address priority WHO​ Diseases

    12

Products and pipeline

  • Assets in the pipeline

    71
  • Number of phase I programmes started in 2023

    8
  • Number of assets in phase III/registration in 2023

    18
  • Major new vaccines and medicines approved in 2023

    4
Vaccines
  • Vaccine preventable diseases identified by WHO

    23/32
  • Vaccine doses delivered each day

    1.5m
  • Children receiving a GSK vaccine each year

    4 in 10
  • Candidate vaccines in our pipeline

    19
Specialty medicines
  • To pioneer HIV treatments in 1980 and leaders in ​HIV innovation

    1st
  • To produce a new medicine ​for Lupus in 50+ years

    1st
  • Investigational medicines in our​ oncology pipeline

    11
General medicines
  • Patients reached with our general medicines over the next ten years

    700m
  • Medicines in our portfolio

    150+
  • Helping millions of people with respiratory conditions to breathe more easily

    50 years
  • In 2023 sales grew to (£)

    10.2bn